NCT06625489View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

November 25, 2024

Study Completion Date

November 25, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Part A: Placebo

Placebo will be administered.

DRUG

Nintedanib

Nintedanib will be administered.

DRUG

GSK3915393

GSK3915393 will be administered.

Trial Locations (2)

89113

GSK Investigational Site, Las Vegas

90630

GSK Investigational Site, Cypress

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06625489 - A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib | Biotech Hunter | Biotech Hunter